The research library
Read the evidence.
Improve the comparison.
What the studies found, what the numbers leave out, and which questions change your shortlist.
Semaglutide vs. tirzepatide: the head-to-head results
SURMOUNT-5 put both treatments in the same trial. That makes the weight-loss comparison stronger—and still leaves several buying decisions unanswered.
Read the SURMOUNT-5 analysisCommon 0–25% scale. Group averages, not individual predictions. Maximum tolerated trial doses; adults without diabetes. Aronne et al. SURMOUNT-5, NEJM (2025).
Follow the question.
10 original analyses across trial results, product evidence and the cost of care.
STEP 1 vs. SURMOUNT-1: comparing weight-loss results
A side-by-side study table is useful. A winner declared by subtracting two separate trial averages is much less reliable.
Read the analysisReading evidenceGLP-1 side effects and dropout: reading the rates
Having a symptom, stopping a medicine and leaving a study are different events. Combining them can make a safety comparison misleading.
Read the analysisProduct evidenceCompounded vs. approved GLP-1s: compare the evidence
A trial result belongs to a studied treatment. Ingredient names, dispensing formats and compounded offers need their own questions.
Read the analysisEmerging treatmentsRetatrutide vs. tirzepatide: compare the evidence, not the hype
Retatrutide has encouraging research behind it, but its regulatory status and the design of its trials change what a comparison can honestly say.
Read the analysisProduct evidenceOral semaglutide vs. injection: what changes?
An approved tablet changes the options. It does not make every oral offer equivalent, or turn separate studies into proof that one route works better.
Read the analysisTreatment comparisonsWegovy vs. Mounjaro: which comparison matters?
Brand names answer a different question from ingredient names. Start with the condition being treated, then match the evidence to the prescription.
Read the analysisTreatment decisionsSwitching semaglutide to tirzepatide: beyond the conversion chart
A treatment change needs a reason, a product-specific plan and follow-up. Trial averages and milligram tables cannot provide that plan.
Read the analysisBeyond weight lossTirzepatide and sleep apnea: a new option with clear boundaries
Zepbound has an approved role in moderate to severe obstructive sleep apnea with obesity. The evidence supports a defined treatment option, not permission to stop PAP.
Read the analysisCost & commitmentA monthly price is not a payment calendar
Why calendar months, 28-day billing and prepaid care create different cash commitments.
Read the worked comparisonEvidence with its boundaries attached.
These are editorial analyses of published research and source documents. We separate reported findings from our interpretation, show funding and study limits, and link to the originals. This is not medical advice or firsthand treatment testing.
How we compareCompare provider offers